Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of ALKS 8700 in Relapsing Remitting Multiple Sclerosis
2015-005160-41Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diroximel fumarate in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Incidence of adverse events. Started Mar 2016; status: completed.
02
Drugs
diroximel fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-005160-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005160-41.